A Study To Describe The Real World Use Of Bosutinib In The UK And

Updated 06/21/2024

Status Completed

Clinical Trial Summary

The purpose of this study is to describe the efficacy and safety of bosutinib in patients with chronic myeloid leukaemia used in a real world setting

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Chronic Myeloid Leukaemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid

Clinical Trial Details

NCT number	NCT02546375
Study type	Observational
Source	Pfizer
Contact
Status	Completed
Phase
Start date	July 15, 2015
Completion date	January 16, 2017

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01475110` - Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib
	Recruiting	`NCT05682924` - Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib
	Completed	`NCT05286528` - Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
	Completed	`NCT01597219` - Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers	Phase 2
	Active, not recruiting	`NCT01699217` - Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
	Completed	`NCT00390897` - Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia	Phase 4
	Active, not recruiting	`NCT01804985` - De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia	Phase 2
	Completed	`NCT01343173` - Multicenter Trial Estimating the Persistence of Molecular Remission in Chronic Myeloid Leukaemia in Long Term After Stopping Imatinib	N/A
	Completed	`NCT05893836` - Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia
	Recruiting	`NCT02001818` - Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia	Phase 2
	Completed	`NCT01621724` - WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study	Phase 1/Phase 2